01 — What is it?
Long-acting amylin analogue under Phase 3 development for weight management. Phase 2 and REDEFINE 1 data show meaningful weight loss, with gastrointestinal adverse events among the common findings.
Database / Research Profiles / Cagrilintide
RESEARCH PROFILE
CAGRILINTIDE
Long-acting amylin analogue
MetabolicStrong human clinical evidence; investigational monotherapy
EVIDENCE SNAPSHOTSTRONG HUMAN CLINICAL EVIDENCE; INVESTIGATIONAL MONOTHERAPY
Cagrilintide itself is investigational; the semaglutide/cagrilintide combination has a large Phase 3 evidence base.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Metabolic. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Cagrilintide itself is investigational; the semaglutide/cagrilintide combination has a large Phase 3 evidence base.
04 — Mechanism / biology
Long-acting amylin analogue under Phase 3 development for weight management. Phase 2 and REDEFINE 1 data show meaningful weight loss, with gastrointestinal adverse events among the common findings.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.